Sinofn Health
Sinofn Health
In the nutraceutical industry, Coenzyme Q10 (CoQ10) remains a cornerstone for mitochondrial health. At SINOFN, we distinguish our supply chain and formulation strategy by providing granular technical support on the conversion and bioavailability profiles of these two distinct forms.
The traditional, stable form. Highly suitable for specific stable-release capsules and cost-effective bulk formulations. Its shelf stability makes it the gold standard for long-term logistics and storage-intensive distribution.
The active, "pre-converted" form. Essential for geriatric care and consumers with compromised metabolic pathways. SINOFN utilizes advanced encapsulation technology to protect this oxygen-sensitive compound, ensuring maximum efficacy at the point of consumption.
SINOFN leverages a 53,000㎡ manufacturing ecosystem. Our Factory 4.0 approach integrates IoT-driven quality control with precision fermentation processes. By utilizing blockchain batch tracking, we provide our global partners with absolute transparency from raw material sourcing to the finished retail unit.
SINOFN Health Co., Ltd., established in 2025 (with foundations back to 2012), is a science-driven OEM partner backed by the Chinese Academy of Sciences. We bridge the gap between academic research and mass-market scalability.
Mrs. GuoHong Liu founded SINOFN with a mission: to make specialized nutrition affordable. From treating rare diseases like PKU to producing premium CoQ10, our goal is "Profit with Purpose."
A: We employ proprietary micro-encapsulation techniques that shield Ubiquinol from oxidation during production, maintaining purity levels consistent with USP standards.
A: Yes, our facilities are ISO 22000, HACCP, and FSSC 22000 certified, ensuring full compliance for EU and North American markets.
A: Absolutely. Our Tianjin R&D center, led by post-docs from the Chinese Academy of Sciences, offers pilot-scale prototyping for rapid market entry.
